Head to Head Review: Sigyn Therapeutics (OTCMKTS:SIGY) vs. Sensus Healthcare (NASDAQ:SRTS)

Sigyn Therapeutics (OTCMKTS:SIGY) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of current recommendations for Sigyn Therapeutics and Sensus Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sigyn Therapeutics	0	0	0	0	N/A
Sensus Healthcare	0	0	2	1	3.33

Sensus Healthcare has a consensus target price of $10.00, indicating a potential upside of 58.98%. Given Sensus Healthcare’s higher probable upside, analysts clearly believe Sensus Healthcare is more favorable than Sigyn Therapeutics.

Earnings and Valuation

This table compares Sigyn Therapeutics and Sensus Healthcare”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sigyn Therapeutics	N/A	N/A	-$4.15 million	N/A	N/A
Sensus Healthcare	$36.37 million	2.84	$490,000.00	$0.29	21.69

Sensus Healthcare has higher revenue and earnings than Sigyn Therapeutics.

Risk and Volatility

Sigyn Therapeutics has a beta of -1.82, indicating that its share price is 282% less volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Profitability

This table compares Sigyn Therapeutics and Sensus Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sigyn Therapeutics	N/A	N/A	-1,095.27%
Sensus Healthcare	18.27%	13.46%	12.10%

Institutional & Insider Ownership

10.0% of Sigyn Therapeutics shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 78.5% of Sigyn Therapeutics shares are held by company insiders. Comparatively, 11.1% of Sensus Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Sensus Healthcare beats Sigyn Therapeutics on 10 of the 11 factors compared between the two stocks.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

About Sensus Healthcare

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.